Maham Fatima
Sat, January 10, 2026 astatine 1:21 PM CST 2 min read
Additionally, Morgan Stanley reduced its terms people for GoodRx from $5 to $4 portion maintaining an Equal Weight standing connected December 18. In a 2026 outlook for the Healthcare Services sector, the steadfast noted that portion healthcare tech and providers connection an charismatic backdrop for alpha-generation, the managed attraction conception continues to struggle.
On December 8, Barclays initiated sum of GoodRx with an Underweight standing and a $3 terms target. While the steadfast established a Neutral outlook connected the broader US healthcare tech and organisation industry, it expressed the astir optimism toward cause distributors. In contrast, Barclays maintained a much cautious and mixed position connected the dental and healthcare IT sub-sectors.
GoodRx Holdings Inc. (NASDAQ:GDRX), unneurotic with its subsidiaries, offers accusation and tools that alteration consumers to comparison prices and prevention connected their medicine cause purchases successful the US.
While we admit the imaginable of GDRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

1 day ago
1





English (CA) ·
English (US) ·
Spanish (MX) ·